{"nctId":"NCT01550744","briefTitle":"A Study of Ustekinumab to Evaluate a \"Subject-tailored\" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis","startDateStruct":{"date":"2012-03"},"conditions":["Psoriasis"],"count":478,"armGroups":[{"label":"Group 1: Approved q12w maintenance regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 45 mg","Drug: Ustekinumab 90 mg","Drug: Placebo"]},{"label":"Group 2: Subject-tailored fixed-interval maintenance regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 45 mg","Drug: Ustekinumab 90 mg","Drug: Placebo"]}],"interventions":[{"name":"Ustekinumab 45 mg","otherNames":[]},{"name":"Ustekinumab 90 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Eligibility Criteria\n\n* Male or female\n* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the first administration of study agent (subjects with concurrent psoriatic arthritis may be enrolled).\n* Have plaque-type psoriasis covering at least 10% of their total BSA at screening and at the time of the first administration of study agent.\n* Have a PGA score of â‰¥ 3 at screening and at the time of the first administration of study agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Visits at Which Participants Achieved a Static Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1)","description":"Clinical responses for week (wk)28 sPGA responders randomized to every 12 weeks (q12wk) fixed-interval dosing (Group 1) vs. patient-tailored fixed-interval dosing (Group 2) were assessed using the static PGA (sPGA) measure. Investigators graded psoriasis lesions for induration (0=no plaque elevation to 5=severe plaque elevation), erythema (0=no evidence of erythema to 5=dusky to deep red coloration), and scaling (0=no evidence of scaling to 5=severe scaling). The sum of the 3 scales is divided by 3 and rounded to obtain a final sPGA score, defined as 0=cleared (except for residual discoloration), 1=minimal, 2=mild, 3=moderate, 4=marked or 5=severe.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"3.07"},{"groupId":"OG001","value":"4.1","spread":"2.93"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With a Static PGA Score of Cleared (0) or Minimal (1) Over Time","description":"Clinical responses for week (wk) 28 sPGA responders randomized to every 12 weeks (q12wk) fixed-interval dosing (Group 1) vs. patient-tailored fixed-interval dosing (Group 2) were assessed using the static PGA (sPGA) measure. Investigators graded psoriasis lesions for induration (0=no plaque elevation to 5=severe plaque elevation), erythema (0=no evidence of erythema to 5=dusky to deep red coloration), and scaling (0=no evidence of scaling to 5=severe scaling). The sum of the 3 scales is divided by 3 and rounded to obtain a final sPGA score, defined as 0=cleared (except for residual discoloration), 1=minimal, 2=mild, 3=moderate, 4=marked or 5=severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"59.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"56.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"68.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"69.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"67.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"65.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"57.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":null},{"groupId":"OG001","value":"63.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"58.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.6","spread":null},{"groupId":"OG001","value":"57.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"56.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null},{"groupId":"OG001","value":"58.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Visits for Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 75 Response","description":"The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 to 72. A PASI 75 response is defined as greater than or equal to (\\>=) 75 percent (%) improvement in PASI score from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"2.31"},{"groupId":"OG001","value":"5.4","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With a PASI 75 Response Over Time","description":"The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 to 72. A PASI 75 response is defined as greater than or equal to (\\>=) 75 percent (%) improvement in PASI score from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"78.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"77.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"82.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null},{"groupId":"OG001","value":"83.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null},{"groupId":"OG001","value":"82.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.7","spread":null},{"groupId":"OG001","value":"83.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"79.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"83.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"79.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"76.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null},{"groupId":"OG001","value":"78.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"75.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"79.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":null},{"groupId":"OG001","value":"77.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":478},"commonTop":["Upper Respiratory Tract Infection","Nasopharyngitis","Sinusitis","Hypertension","Arthralgia"]}}}